Cargando…
Combinatorial Therapies in Thyroid Cancer: An Overview of Preclinical and Clinical Progresses
Accounting for about 2% of cancers diagnosed worldwide, thyroid cancer has caused about 41,000 deaths in 2018. Despite significant progresses made in recent decades in the treatment of thyroid cancer, many resistances to current monotherapies are observed. In our complete review, we report all treat...
Autores principales: | Laetitia, Gheysen, Sven, Saussez, Fabrice, Journe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7226736/ https://www.ncbi.nlm.nih.gov/pubmed/32235612 http://dx.doi.org/10.3390/cells9040830 |
Ejemplares similares
-
New Treatment Strategy Targeting Galectin-1 against Thyroid Cancer
por: Gheysen, Laetitia, et al.
Publicado: (2021) -
Galectins and Carcinogenesis: Their Role in Head and Neck Carcinomas and Thyroid Carcinomas
por: Kindt, Nadège, et al.
Publicado: (2017) -
PRIMA-1 and PRIMA-1(Met) (APR-246): From Mutant/Wild Type p53 Reactivation to Unexpected Mechanisms Underlying Their Potent Anti-Tumor Effect in Combinatorial Therapies
por: Perdrix, Anne, et al.
Publicado: (2017) -
Galectin-1 is a diagnostic marker involved in thyroid cancer progression
por: Arcolia, Vanessa, et al.
Publicado: (2017) -
Combination of galectin-3, CK19 and HBME-1 immunostaining improves the diagnosis of thyroid cancer
por: Arcolia, Vanessa, et al.
Publicado: (2017)